BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 36658755)

  • 1. Androgen deprivation therapy in men with prostate cancer is not associated with COVID-2019 infection.
    Davidsson S; Messing Eriksson A; Udumyan R; Swanholm P; Lewin Lundh M; Widing C; Lindlöf C; Fridfeldt J; Andersson SO; Fall K
    Prostate; 2023 May; 83(6):555-562. PubMed ID: 36658755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between SARS-CoV-2 infection and disease severity among prostate cancer patients on androgen deprivation therapy: a systematic review and meta-analysis.
    Sari Motlagh R; Abufaraj M; Karakiewicz PI; Rajwa P; Mori K; Mun DH; Shariat SF
    World J Urol; 2022 Apr; 40(4):907-914. PubMed ID: 34477955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impacts of androgen deprivation therapy on the risks and outcomes of SARS-CoV-2 infection in patients with prostate cancer.
    Huang YB; Li WL; Sun M; Duan X; Wang YT; Zhang LX; Xin ZH; Yun ZF; Fan B; Li XC
    Asian J Androl; 2023; 25(3):366-374. PubMed ID: 35915542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532).
    Montopoli M; Zumerle S; Vettor R; Rugge M; Zorzi M; Catapano CV; Carbone GM; Cavalli A; Pagano F; Ragazzi E; Prayer-Galetti T; Alimonti A
    Ann Oncol; 2020 Aug; 31(8):1040-1045. PubMed ID: 32387456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19.
    Schmidt AL; Tucker MD; Bakouny Z; Labaki C; Hsu CY; Shyr Y; Armstrong AJ; Beer TM; Bijjula RR; Bilen MA; Connell CF; Dawsey SJ; Faller B; Gao X; Gartrell BA; Gill D; Gulati S; Halabi S; Hwang C; Joshi M; Khaki AR; Menon H; Morris MJ; Puc M; Russell KB; Shah NJ; Sharifi N; Shaya J; Schweizer MT; Steinharter J; Wulff-Burchfield EM; Xu W; Zhu J; Mishra S; Grivas P; Rini BI; Warner JL; Zhang T; Choueiri TK; Gupta S; McKay RR
    JAMA Netw Open; 2021 Nov; 4(11):e2134330. PubMed ID: 34767021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Susceptibility to SARS-Cov-2 infection and risk for severe COVID-19 in patients with prostate cancer on androgen deprivation therapy.
    Gedeborg R; Loeb S; Styrke J; Kiiski-Berggren R; Garmo H; Stattin P
    Int J Cancer; 2022 Dec; 151(11):1925-1934. PubMed ID: 35802468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship Between Androgen Deprivation Therapy for Prostate Cancer and Risk of SARS-CoV-2 Infection: A Systematic Review and Meta-Analysis.
    Kim DK; Park JJ; Yang WJ; Doo SW; Kim JH
    J Korean Med Sci; 2022 Aug; 37(31):e237. PubMed ID: 35942555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Androgen Deprivation Therapy on COVID-19 in Patients with Prostate Cancer: A Systematic Review and Meta-Analysis.
    Karimi A; Nowroozi A; Alilou S; Amini E
    Urol J; 2021 Jul; 18(6):577-584. PubMed ID: 34302737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Impact of Androgen Deprivation Therapy on COVID-19 Illness in Men With Prostate Cancer.
    Shah NJ; Patel VG; Zhong X; Pina L; Hawley JE; Lin E; Gartrell BA; Febles VA; Wise DR; Qin Q; Mellgard G; Joshi H; Nauseef JT; Green DA; Vlachostergios PJ; Kwon DH; Huang F; Liaw B; Tagawa S; Kantoff P; Morris MJ; Oh WK
    JNCI Cancer Spectr; 2022 May; 6(3):. PubMed ID: 35657341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prostate cancer, androgen deprivation, and risk of COVID-19 infection : A systematic review and meta-analysis].
    Manolache NG; Mjaess G; Diamand R; Albisinni S; Roumeguère T
    Prog Urol; 2022 Dec; 32(16):1421-1430. PubMed ID: 36163317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of androgen deprivation therapy on the severity of COVID-19 in prostate cancer patients.
    Jiménez-Alcaide E; García-Fuentes C; Hernández V; De la Peña E; Pérez-Fernández E; Castro A; Caballero-Perea B; Guijarro A; Llorente C
    Prostate; 2021 Dec; 81(16):1349-1354. PubMed ID: 34517429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen deprivation therapy, comorbidity, cancer stage and mortality from COVID-19 in men with prostate cancer.
    Gedeborg R; Lindhagen L; Loeb S; Styrke J; Garmo H; Stattin P
    Scand J Urol; 2022 Apr; 56(2):104-111. PubMed ID: 34939533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen Deprivation Therapy in Men with Prostate Cancer Does Not Affect Risk of Infection with SARS-CoV-2.
    Klein EA; Li J; Milinovich A; Schold JD; Sharifi N; Kattan MW; Jehi L
    J Urol; 2021 Feb; 205(2):441-443. PubMed ID: 32897764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen deprivation therapy and excess mortality in men with prostate cancer during the initial phase of the COVID-19 pandemic.
    Gedeborg R; Styrke J; Loeb S; Garmo H; Stattin P
    PLoS One; 2021; 16(10):e0255966. PubMed ID: 34618806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical impact of androgen deprivation therapy on SARS-CoV-2 infection rates and disease severity.
    Kazan Ö; Çulpan M; Efiloğlu Ö; Atiş G; Yildirim A
    Turk J Urol; 2021 Nov; 47(6):495-500. PubMed ID: 35118968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Population-Level Analysis of the Protective Effects of Androgen Deprivation Therapy Against COVID-19 Disease Incidence and Severity.
    Lee KM; Heberer K; Gao A; Becker DJ; Loeb S; Makarov DV; Gulanski B; DuVall SL; Aslan M; Lee J; Shih MC; Lynch JA; Hauger RL; Rettig M
    Front Med (Lausanne); 2022; 9():774773. PubMed ID: 35602518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is COVID-19 a risk factor for progression of benign prostatic hyperplasia and exacerbation of its related symptoms?: a systematic review.
    Haghpanah A; Masjedi F; Salehipour M; Hosseinpour A; Roozbeh J; Dehghani A
    Prostate Cancer Prostatic Dis; 2022 Mar; 25(1):27-38. PubMed ID: 34007019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severe acute respiratory syndrome coronavirus 2 infection in patients with prostate cancer: A critical review.
    Caffo O; Messina M; Veccia A; Kinspergher S; Maines F; Messina C
    Crit Rev Oncol Hematol; 2021 Nov; 167():103491. PubMed ID: 34626792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Depressive symptoms are found to be potential adverse effects of androgen deprivation therapy in older prostate cancer patients: A 15-month prospective, observational study.
    Zhang Z; Yang L; Xie D; Shi H; Li G; Yu D
    Psychooncology; 2017 Dec; 26(12):2238-2244. PubMed ID: 28474429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mapping European Association of Urology Guideline Practice Across Europe: An Audit of Androgen Deprivation Therapy Use Before Prostate Cancer Surgery in 6598 Cases in 187 Hospitals Across 31 European Countries.
    MacLennan S; Azevedo N; Duncan E; Dunsmore J; Fullwood L; Lumen N; Plass K; Ribal MJ; Roobol MJ; Nieboer D; Schouten N; Skolarus TA; Smith EJ; N'Dow J; Mottet N; Briganti A;
    Eur Urol; 2023 May; 83(5):393-401. PubMed ID: 36639296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.